Method of detecting and treating tuberous sclerosis complex associated disorders

Abstract

Disclosed are methods of detecting and treating tuberous sclerosis complex associated disorders. Also disclosed are methods of identifying agents for treating tuberous sclerosis complex associated disorders.

1 . An isolated antibody that immunospecifically binds to an NMB polypeptide. 
     
     
         2 . The antibody of  claim 1 , wherein the NMB polypeptide comprises the amino acid sequence of TSC122. 
     
     
         3 . The antibody of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         4 . The antibody of  claim 1 , wherein the antibody is a human monoclonal antibody. 
     
     
         5 . The antibody of  claim 1 , wherein the antibody is a humanized antibody. 
     
     
         6 . A pharmaceutical composition comprising the antibody of  claim 1  and a carrier. 
     
     
         7 . A method of treating a disease or disorder characterized by aberrant expression or activity of NMB, said method comprising administering an isolated antibody that modulates expression or activity of NMB. 
     
     
         8 . The method of  claim 7 , wherein the antibody inhibits expression or activity of NMB. 
     
     
         9 . The method of  claim 7 , wherein the disease or disorder characterized by aberrant expression or activity of NMB is a cancer. 
     
     
         10 . The method of  claim 9 , wherein the cancer is breast cancer. 
     
     
         11 . The method of  claim 9 , wherein the cancer is selected from melanoma, renal carcinoma, lung carcinoma, and a CNS cancer. 
     
     
         12 . The method of  claim 9 , wherein the cancer is a metastasis from a primary tumor. 
     
     
         13 . The method of  claim 12 , wherein the primary tumor is selected from a breast cancer tumor, a melanoma, a renal cell carcinoma, a lung carcinoma and a CNS cancer. 
     
     
         14 . The method of  claim 7 , wherein the antibody is administered prior to the manifestation of a symptom associated with aberrant expression or activity of NMB, thereby delaying the progression of the disease or disorder. 
     
     
         15 . The method of  claim 7 , wherein the antibody is administered systematically or locally. 
     
     
         16 . The method of  claim 7 , wherein the antibody is a monoclonal antibody. 
     
     
         17 . The method of  claim 7 , wherein the antibody is a human monoclonal antibody. 
     
     
         18 . The method of  claim 7 , wherein the antibody is a humanized antibody.